Press Release

SOUTH SAN FRANCISCO, Calif. — Pliant Therapeutics, Inc. today announced that it has raised $62 million in a Series B financing. The funds will support the initiation and proof-of-concept clinical trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC), as well as ongoing drug discovery programs targeting other fibrotic diseases. The financing was led by Cowen Healthcare […]

SAN FRANCISCO — Verge Genomics, a drug discovery company utilizing machine learning to develop new therapeutics, announced today that it has raised $32 million in Series A financing led by DFJ. New biotech investors WuXi AppTec’s Corporate Venture Fund, ALS Investment Fund, Agent Capital, and OS Fund also participated in the round. The oversubscribed round […]

AMBRIDGE, Mass., June 26, 2018 — Skyhawk Therapeutics, Inc. (“Skyhawk”), today announced the closing of a new $40 million equity investment round alongside its recently announced $60 million strategic collaboration, bringing total new capital into the company to over $100 million. Proceeds will be used for development of Skyhawk’s innovative STAR* technology platform to discover and develop small molecules that correct mutations in […]

DURHAM, North Carolina, USA, June 26 2018 – Precision BioSciences today announced the closing of an oversubscribed $110M Series B financing to further product development efforts based on its ARCUS® genome editing platform. The financing was led by ArrowMark Partners and was joined by new investors Franklin Templeton Investments, Cowen Healthcare Investments, Brace Pharma Capital, Pontifax […]

EVANSTON, Ill., June 20, 2018 — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced the pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Aptinyx. In addition, Aptinyx has granted […]

London, UK, December 20, 2017 — Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B financing. Baillie Gifford and ORI Capital co-led the financing with significant new investments from Temasek and Cowen Healthcare […]

EVANSTON, Ill., Dec 18, 2017 –Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage Capital, Agent Capital, HBM Healthcare Investments, Nan […]